Date: 2016-01-14
Type of information: Nomination
Compound:
Company: Affimed (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 14, 2016, Affimed announced that Dr. Andrew Evens has joined Affimed’s Scientific Advisory Board. Dr. Evens is Professor of Medicine at Tufts University School of Medicine and he is Chief of the Division of Hematology/Oncology and Director of the Tufts Cancer Center at Tufts Medical Center in Boston, Massachusetts. He was also named the Chan Soon-Shiong Endowed Scholar in Precision Medicine at Tufts Medical Center.
Dr. Evens completed his Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center (RHLCCC) where he also remained on faculty for approximately 15 years. Before arriving to Tufts Medical Center, he was a faculty member at the University of Massachusetts Medical School and the UMass Memorial Cancer Center where he served as the Deputy Director for the Cancer Center. Dr. Evens’ focus is in the biology, prognosis and treatment of Non-Hodgkin lymphoma and Hodgkin disease/lymphoma. He has designed and conducted a multitude of clinical trials in lymphoid malignancies and has authored or co-authored more than 100 original articles in this field. Dr. Evens also maintains a R01-funded translational lymphoma laboratory examining lymphoma biology, signal transduction pathways, free radical-mediated biology and the development of novel targeted agents for the treatment of lymphoma. Additionally, Dr. Evens is an Associate Editor for the British Journal of Haematology; he chairs the Hematology Panel for the VA R01 Scientific Merit Review committee; and he is a primary member of the Hodgkin Lymphoma Working Group for the NIH and NCI Steering Committee.
Financial terms:
Latest news:
